Latest

Aug 13, 2026, 13:11 Srini Pallia Has More Large Deals at Wipro. He Still Needs a Growth Model That Pays

Aug 12, 2026, 15:05 Mitsuko Tottori Must Make Japan Airlines Safer and Less Dependent on the Airline Cycle

Aug 11, 2026, 13:27 Shuntaro Furukawa Won the Switch 2 Launch. The Second Year Will Define Its Economics

Aug 10, 2026, 17:04 Nithin Kamath Built Zerodha for a Boom. Regulation Is Testing the Model in Reverse

Aug 09, 2026, 10:46 Ravi Kumar S Has Restarted Cognizant’s Growth. The AI Builder Strategy Must Now Deepen It

Aug 08, 2026, 18:14 Noubar Afeyan’s Venture Factory Faces the Test That Matters: Translation

Aug 07, 2026, 16:25 Assaf Rappaport Sold Wiz to Google. Now He Must Prove Independence Can Survive Integration

Aug 06, 2026, 18:49 Tony Fernandes Finally Has a Clean Capital A. Now He Must Prove What Remains Is a Business

Clinical Trials

A National Institute of Allergy and Infectious Diseases scientist working with samples in a vaccine research laboratory

Thailand Courts Korean Biotech With a $42.7 Billion Wellness Market

Thailand’s deputy prime minister invited Korean investment in vaccines, medical devices, wellness and future food at a July 22 forum in Seoul.

Uğur Şahin, Chief Executive Officer and Co-Founder of BioNTech

Uğur Şahin’s US$11.1 Billion Pumitamig Alliance Now Faces the Phase III Arithmetic

Pumitamig has moved from BioNTech’s US$800 million Biotheus acquisition to an alliance worth up to US$11.1 billion. Uğur Şahin must show that encouraging lung-cancer signals survive global Phase III trials and a crowded competitive field.